Gonococcal iridocyclitis
ICD-10 A54.32 is a billable code used to indicate a diagnosis of gonococcal iridocyclitis.
Gonococcal iridocyclitis is an inflammatory condition of the iris and ciliary body caused by the Neisseria gonorrhoeae bacterium, which is primarily known for causing gonorrhea, a sexually transmitted infection (STI). This condition can occur when the bacteria spread from the genital tract to the eye, leading to symptoms such as redness, pain, photophobia, and blurred vision. The inflammation can result in complications such as glaucoma or vision loss if not treated promptly. Diagnosis typically involves a thorough clinical examination, including slit-lamp examination, and may require laboratory confirmation through cultures or polymerase chain reaction (PCR) testing. Treatment usually involves systemic antibiotics, with ceftriaxone being the first-line therapy. Additionally, managing associated symptoms and complications is crucial for preserving vision and preventing further ocular damage. Gonococcal iridocyclitis is a rare but serious manifestation of gonococcal infection, highlighting the importance of early detection and treatment of STIs.
Detailed clinical notes on ocular examination findings, including visual acuity and slit-lamp examination results.
Patients presenting with eye pain, redness, and a history of gonorrhea or other STIs.
Documentation must clearly link the ocular symptoms to the gonococcal infection.
Comprehensive history of sexual activity, STI screening results, and treatment plans.
Patients with systemic gonococcal infections presenting with ocular symptoms.
Coordination with ophthalmology for management of ocular symptoms.
Used when a new patient presents with symptoms of gonococcal iridocyclitis.
Complete history and examination findings.
Ophthalmologists should document the link to the STI.
Common symptoms include eye pain, redness, photophobia, and blurred vision. Patients may also have a history of gonorrhea or other STIs.
Treatment typically involves systemic antibiotics, with ceftriaxone being the first-line therapy. Management of symptoms and complications is also important.
